AI Agentic Workflow for Genetic and Genomic Target Discovery

Manual integration of GWAS, CRISPR screen, and functional genomics data is a sequential, expert-driven process taking 6-12 months. An automated workflow orchestrates agents to mine public repositories (UK Biobank, DepMap), perform statistical fine-mapping, and cross-reference tractability databases in parallel. This compresses the initial target hypothesis generation phase, allowing discovery teams to build a pipeline faster and respond to emerging genetic evidence with agility.

Targets with human genetic support have a >2x higher likelihood of clinical approval. This workflow embeds genetic evidence as a non-negotiable filter, automating the retrieval and scoring of variant-to-gene links, pathway enrichment, and Mendelian randomization studies. By systematically prioritizing targets with causal human data over those derived solely from animal models, the pipeline's foundational quality improves, de-risking downstream investments in chemistry and clinical development.

Blind virtual screening against thousands of putative targets is computationally wasteful. This workflow applies genetic and functional prior art to produce a focused, high-confidence target shortlist (e.g., 10-20 targets vs. 100+). This precision reduces cloud HPC spend for downstream molecular docking and screening campaigns by ~80% and focuses expensive CRO functional validation assays on the most promising biology, improving the return on every R&D dollar.

Target selection committees often rely on fragmented slide decks and expert opinion. This workflow generates a structured, evidence-backed dossier for each candidate, linking genetic variants, fine-mapping confidence scores, druggability assessments, and competitive landscape. This creates a transparent, audit-ready decision trail that strengthens internal governance, supports regulatory interactions (e.g., FDA's Genomics Guidance), and provides a clear rationale for portfolio investment and deprioritization.

Missing a key patent or a competitor's emerging genetic publication can invalidate years of work. The workflow deploys agents to continuously monitor patent filings (e.g., USPTO, Espacenet) and preprint servers, extracting claims related to target biology. It automatically flags conflicts or white space, enabling proactive IP strategy and ensuring the pipeline is built on novel, defensible ground. This turns competitive intelligence from a periodic manual review into a real-time operational layer.

Building a sustainable advantage requires moving from project-based analysis to a platform. This workflow codifies the target discovery process into a reusable, containerized pipeline (e.g., using LangGraph for orchestration, Neo4j for the knowledge graph). It allows new disease areas or genetic datasets to be onboarded in days, not months, creating a scalable operating model that increases research throughput without linearly increasing bioinformatician headcount.

This agent automates the repetitive, error-prone task of pulling and standardizing data from fragmented public repositories (e.g., UK Biobank, GWAS Catalog, DepMap, GTEx). It handles API calls, file parsing, and schema mapping to create a unified, queryable genomic evidence layer. The implementation uses secure cloud storage and version control for all source data, ensuring reproducibility and auditability for downstream analyses.

This specialized component automates the computational heavy lifting of pinpointing causal variants from broad genetic association signals. It orchestrates Bayesian fine-mapping pipelines (e.g., using FINEMAP, SuSiE) across loci in parallel on cloud HPC, adjusting for linkage disequilibrium and functional annotations. The engine outputs a ranked list of putative causal genes with posterior probabilities, replacing weeks of manual analysis with a standardized, high-throughput process.

This agent automates the critical business assessment of whether a genetically implicated target is commercially viable. It queries pharmacological databases (e.g., ChEMBL, DrugBank), protein structure repositories, and literature to score targets based on known ligandability, antibody developability, tissue expression, and safety profiles. The agent synthesizes this into a tractability score, preventing teams from wasting resources on biologically valid but undruggable targets.

This is the central decision layer that automates the final prioritization. It ingests outputs from all upstream agents—genetic evidence strength, fine-mapping confidence, tractability scores, and competitive landscape data—and applies a configurable, multi-parameter optimization (MPO) algorithm defined by portfolio strategy. The orchestrator generates a ranked target list with supporting rationale, ready for project team review and governance approval, replacing subjective, spreadsheet-based ranking meetings.

This agent automates the transition from computational discovery to wet-lab validation. For each high-priority target, it drafts a proposed experimental validation plan by retrieving standard protocols (e.g., CRISPR knockout, siRNA screens), checking internal reagent inventory, and estimating timelines. It creates tickets in lab management systems and populates project wikis, ensuring a smooth, traceable handoff that accelerates the initiation of confirmatory biology.

This foundational component automates the compliance and reliability requirements for a regulated R&D environment. It logs every agent decision, data source, and model version used in the workflow, creating an immutable audit trail for internal and regulatory review. It continuously monitors the performance of underlying AI/ML models for prediction drift and triggers retraining pipelines, ensuring the long-term validity and defensibility of the automated discovery process.